Press coverage about Vericel Corporation (NASDAQ:VCEL) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vericel Corporation earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.6387490373683 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s analysis:
- Critical Contrast: Kadmon Holdings (KDMN) & Vericel Corporation (VCEL) (americanbankingnews.com)
- Glistening Stock’s Review: Vericel Corporation (NASDAQ: VCEL) – Alpha Beta Stock (alphabetastock.com)
- ETFs with exposure to Vericel Corp. : November 8, 2017 (finance.yahoo.com)
- Edited Transcript of VCEL earnings conference call or presentation 7-Nov-17 1:00pm GMT (finance.yahoo.com)
- Vericel Corporation (VCEL) Issues Earnings Results (americanbankingnews.com)
Several research analysts recently issued reports on the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 target price on shares of Vericel Corporation in a research report on Thursday, August 10th. BTIG Research set a $6.00 target price on Vericel Corporation and gave the company a “buy” rating in a research report on Wednesday, August 9th.
Vericel Corporation (NASDAQ:VCEL) opened at $3.90 on Tuesday. Vericel Corporation has a 1 year low of $2.15 and a 1 year high of $6.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.50 and a quick ratio of 2.22.
Vericel Corporation (NASDAQ:VCEL) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. Vericel Corporation had a negative return on equity of 265.45% and a negative net margin of 45.11%. The company had revenue of $14.26 million for the quarter. equities research analysts anticipate that Vericel Corporation will post -0.63 earnings per share for the current year.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.